CD19/CD22 CAR-T is under clinical development by Shanghai Unicar-Therapy Bio-Medicine Technology and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CD19/CD22 CAR-T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CD19/CD22 CAR-T overview
The therapeutic candidate is under development for the treatment of relapsed and refractory B cell non-Hodgkin's lymphoma, diffuse large b-cell lymphoma, primary mediastinal large B-cell lymphoma, follicular cell lymphoma, mantle cell lymphoma and b-cell acute lymphoblastic leukemia. The therapeutic candidate consists of chimeric antigen receptor (CAR) modified T-cells, which is administered through parenteral and intravenous route. It acts by targeting CD19 and CD22 expressing cancer cells.
Shanghai Unicar-Therapy Bio-Medicine Technology overview
Shanghai Unicar-Therapy Bio-Medicine Technology., is a pharmaceutical company and a tumor immunotherapy technology developer. The company is headquartered China.
For a complete picture of CD19/CD22 CAR-T’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
